B. Riley Financial Initiates Coverage on AgomAb Therapeutics (NASDAQ:AGMB)

Research analysts at B. Riley Financial initiated coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a report issued on Thursday. The brokerage set a “buy” rating and a $34.00 price target on the stock. B. Riley Financial’s price objective points to a potential upside of 193.10% from the company’s previous close.

Separately, HC Wainwright initiated coverage on AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.00.

AgomAb Therapeutics Stock Performance

Shares of AGMB stock opened at $11.60 on Thursday. The stock has a 50-day moving average of $11.71. AgomAb Therapeutics has a one year low of $8.75 and a one year high of $17.82.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.